Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI

• Published in: Zhongliu fangzhi yanjiu Vol. 52; no. 6; pp. 429 - 435
• Main Authors: Zeng, Yiming, Fang, Wenfeng, Zhang, Li
• Format: Journal Article
• Language: Chinese; English
• Published: Tianjin China Anti-Cancer Association 2025; Magazine House of Cancer Research on Prevention and Treatment
• Subjects: Customization; egfr-mutant nsclc; egfr-tki resistance; Epidermal growth factor receptors; Immunotherapy; Kinases; Lung cancer; Mutants; Non-small cell lung carcinoma; novel drugs; Precision medicine; Quality of life; Small cell lung carcinoma; targeted therapy; Tyrosine; Tyrosine kinase inhibitors
• ISSN: 1000-8578
• DOI: 10.3971/j.issn.1000-8578.2025.24.1209

EGFR-mutant non-small cell lung cancer (NSCLC) is a common type of lung cancer, with EGFR tyrosine kinase inhibitors (EGFR-TKIs) being the standard first-line treatment. However, most patients with NSCLC eventually develop resistance to EGFR-TKIs. Studies on the mechanism underlying EGFR-TKI resistance have driven the development of personalized and precision medicine. Current strategies to address resistance include targeted therapy, immunotherapy, and novel drug treatments. Selecting the appropriate personalized treatment plan is crucial for improving the survival rate and quality of life of patients with EGFR-mutant NSCLC. Thus, this study provides a brief review of the current status and future perspectives in the treatment of EGFR-mutant NSCLC after progression on EGFR-TKI therapy.